Molecular Basis of Extramural Vascular Invasion (EMVI) in Colorectal Carcinoma.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
22
03
2022
accepted:
27
06
2022
pubmed:
3
8
2022
medline:
14
10
2022
entrez:
2
8
2022
Statut:
ppublish
Résumé
Extramural vascular invasion (EMVI) is a known poor prognostic factor in colorectal carcinoma; however, its molecular basis has not been defined. This study aimed to assess the expression of molecular markers in EMVI positive colorectal carcinoma to understand their tumor microenvironment. Immunohistochemistry was performed on tissue microarrays of surgically resected colorectal cancer specimens for immunological markers, and BRAFV600E mutation (and on the tissue blocks for mismatch repair proteins). Automated quantification was used for CD8, LAG3, FOXP3, PU1, and CD163, and manual quantification was used for PDL1, HLA I markers (beta-2 microglobulin, HC10), and HLA II. The Wilcoxon rank-sum test was used to compare EMVI positive and negative tumors. A logistic regression model was fitted to assess the predictive effect of biomarkers on EMVI. There were 340 EMVI positive and 678 EMVI negative chemo naïve tumors. PDL1 was barely expressed on tumor cells (median 0) in the entire cohort. We found a significantly lower expression of CD8, LAG3, FOXP3, PU1 cells, PDL1 positive macrophages, and beta-2 microglobulin on tumor cells in the EMVI positive subset (p ≤ 0.001). There was no association of BRAFV600E or deficient mismatch repair proteins (dMMR) with EMVI. PU1 (OR 0.8, 0.7-0.9) and low PDL1 (OR 1.6, 1.1-2.3) independently predicted EMVI on multivariate logistic regression among all biomarkers examined. There is a generalized blunting of immune response in EMVI positive colorectal carcinoma, which may contribute to a worse prognosis. Tumor-associated macrophages seem to play the most significant role in determining EMVI.
Sections du résumé
BACKGROUND
BACKGROUND
Extramural vascular invasion (EMVI) is a known poor prognostic factor in colorectal carcinoma; however, its molecular basis has not been defined. This study aimed to assess the expression of molecular markers in EMVI positive colorectal carcinoma to understand their tumor microenvironment.
METHODS
METHODS
Immunohistochemistry was performed on tissue microarrays of surgically resected colorectal cancer specimens for immunological markers, and BRAFV600E mutation (and on the tissue blocks for mismatch repair proteins). Automated quantification was used for CD8, LAG3, FOXP3, PU1, and CD163, and manual quantification was used for PDL1, HLA I markers (beta-2 microglobulin, HC10), and HLA II. The Wilcoxon rank-sum test was used to compare EMVI positive and negative tumors. A logistic regression model was fitted to assess the predictive effect of biomarkers on EMVI.
RESULTS
RESULTS
There were 340 EMVI positive and 678 EMVI negative chemo naïve tumors. PDL1 was barely expressed on tumor cells (median 0) in the entire cohort. We found a significantly lower expression of CD8, LAG3, FOXP3, PU1 cells, PDL1 positive macrophages, and beta-2 microglobulin on tumor cells in the EMVI positive subset (p ≤ 0.001). There was no association of BRAFV600E or deficient mismatch repair proteins (dMMR) with EMVI. PU1 (OR 0.8, 0.7-0.9) and low PDL1 (OR 1.6, 1.1-2.3) independently predicted EMVI on multivariate logistic regression among all biomarkers examined.
CONCLUSION
CONCLUSIONS
There is a generalized blunting of immune response in EMVI positive colorectal carcinoma, which may contribute to a worse prognosis. Tumor-associated macrophages seem to play the most significant role in determining EMVI.
Identifiants
pubmed: 35917013
doi: 10.1245/s10434-022-12212-w
pii: 10.1245/s10434-022-12212-w
doi:
Substances chimiques
Forkhead Transcription Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7372-7382Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. Society of Surgical Oncology.
Références
Harrison JC, Dean PJ, El-Zeky F, Vander Zwaag R. From Dukes through Jass: pathological prognostic indicators in rectal cancer. Hum Pathol. 1994;25(5):498–505. https://doi.org/10.1016/0046-8177(94)90122-8 .
doi: 10.1016/0046-8177(94)90122-8
pubmed: 8200644
Ale Ali H, Kirsch R, Razaz S, et al. Extramural venous invasion in rectal cancer: overview of imaging, histopathology, and clinical implications. Abdom Radiol (NY). 2019;44(1):1–10. https://doi.org/10.1007/s00261-018-1673-2 .
doi: 10.1007/s00261-018-1673-2
pubmed: 29967984
Freedman LS, Macaskill P, Smith AN. Multivariate analysis of prognostic factors for operable rectal cancer. Lancet. 1984;2(8405):733–6. https://doi.org/10.1016/s0140-6736(84)92636-9 .
doi: 10.1016/s0140-6736(84)92636-9
pubmed: 6148482
Siddiqui MRS, Simillis C, Hunter C, et al. A meta-analysis comparing the risk of metastases in patients with rectal cancer and MRI-detected extramural vascular invasion (mrEMVI) vs mrEMVI-negative cases. Br J Cancer. 2017;116(12):1513–9. https://doi.org/10.1038/bjc.2017.99 .
doi: 10.1038/bjc.2017.99
pubmed: 28449006
pmcid: 5518867
Qwaider YZ, Sell NM, Stafford CE, et al. Adjuvant chemotherapy benefits on patients with extramural vascular invasion in stages II and III colon cancer. J Gastrointest Surg. 2021;25(8):2019–25. https://doi.org/10.1007/s11605-020-04810-4 .
doi: 10.1007/s11605-020-04810-4
pubmed: 33009639
Gunal A, Hui P, Kilic S, et al. KRAS mutations are associated with specific morphologic features in colon cancer. J Clin Gastroenterol. 2013;47(6):509–14. https://doi.org/10.1097/MCG.0b013e3182703030 .
doi: 10.1097/MCG.0b013e3182703030
pubmed: 23090042
Williamson JS, Jones HG, Williams N, et al. Extramural vascular invasion and response to neoadjuvant chemoradiotherapy in rectal cancer: Influence of the CpG island methylator phenotype. World J Gastrointest Oncol. 2017;9(5):209–17. https://doi.org/10.4251/wjgo.v9.i5.209 .
doi: 10.4251/wjgo.v9.i5.209
pubmed: 28567185
pmcid: 5434388
Bae JM, Kim JH, Cho NY, Kim TY, Kang GH. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. Br J Cancer. 2013;109(4):1004–12. https://doi.org/10.1038/bjc.2013.430 .
doi: 10.1038/bjc.2013.430
pubmed: 23900220
pmcid: 3749584
Kokelaar RF, Jones HG, Williamson J, et al. DNA hypermethylation as a predictor of extramural vascular invasion (EMVI) in rectal cancer. Cancer Biol Ther. 2018;19(3):214–21. https://doi.org/10.1080/15384047.2017.1416933 .
doi: 10.1080/15384047.2017.1416933
pubmed: 29260978
pmcid: 5790361
Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–91. https://doi.org/10.1016/S1470-2045(17)30422-9 .
doi: 10.1016/S1470-2045(17)30422-9
pubmed: 28734759
pmcid: 6207072
Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20. https://doi.org/10.1056/NEJMoa1500596 .
doi: 10.1056/NEJMoa1500596
pubmed: 26028255
pmcid: 4481136
Talbot IC, Ritchie S, Leighton MH, Hughes AO, Richard Bussey HJ, Morson BC. Spread of rectal cancer within veins. Am J Surg. 1981;141(1):15–7. https://doi.org/10.1016/0002-9610(81)90004-0 .
doi: 10.1016/0002-9610(81)90004-0
pubmed: 7457719
Leijssen LGJ, Dinaux AM, Amri R, et al. Impact of intramural and extramural vascular invasion on stage II-III colon cancer outcomes. J Surg Oncol. 2019;119(6):749–57. https://doi.org/10.1002/jso.25367 .
doi: 10.1002/jso.25367
pubmed: 30644557
pmcid: 6629581
Quirke P, Morris E. Reporting colorectal cancer. Histopathology. 2007;50(1):103–12. https://doi.org/10.1111/j.1365-2559.2006.02543.x .
doi: 10.1111/j.1365-2559.2006.02543.x
pubmed: 17204025
Morris M, Platell C, de Boer B, McCaul K, Iacopetta B. Population-based study of prognostic factors in stage II colonic cancer. Br J Surg. 2006;93(7):866–71. https://doi.org/10.1002/bjs.5345 .
doi: 10.1002/bjs.5345
pubmed: 16622901
Washington MK, Berlin J, Branton P, et al. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med. 2009;133(10):1539–51. https://doi.org/10.1043/1543-2165-133.10.1539 .
doi: 10.1043/1543-2165-133.10.1539
pubmed: 19792043
pmcid: 2901838
Williams GT, Quirke P, Shepherd NA. Dataset for colorectal cancer.
Loughrey MB, Webster F, Arends MJ, et al. Dataset for pathology reporting of colorectal cancer: recommendations from the international collaboration on cancer reporting (ICCR). Ann Surg. 2022;275(3):e549–61. https://doi.org/10.1097/SLA.0000000000005051 .
doi: 10.1097/SLA.0000000000005051
pubmed: 34238814
De Salins AGD, Tachon G, Cohen R, et al. Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer. ESMO Open. 2021;6(3):100120. https://doi.org/10.1016/j.esmoop.2021.100120 .
doi: 10.1016/j.esmoop.2021.100120
Talbot IC, Ritchie S, Leighton M, Hughes AO, Bussey HJ, Morson BC. Invasion of veins by carcinoma of rectum: method of detection, histological features and significance. Histopathology. 1981;5(2):141–63. https://doi.org/10.1111/j.1365-2559.1981.tb01774.x .
doi: 10.1111/j.1365-2559.1981.tb01774.x
pubmed: 7216178
Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–6. https://doi.org/10.1038/nm.3967 .
doi: 10.1038/nm.3967
pubmed: 26457759
pmcid: 4636487
Wielandt AM, Villarroel C, Hurtado C, et al. Characterization of patients with sporadic colorectal cancer following the new consensus molecular subtypes (CMS). Rev Med Chil. 2017;145(4):419–30. https://doi.org/10.4067/S0034-98872017000400001 .
doi: 10.4067/S0034-98872017000400001
pubmed: 28748988
Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–4. https://doi.org/10.1126/science.1129139 .
doi: 10.1126/science.1129139
pubmed: 17008531
Hu G, Li Z, Wang S. Tumor-infiltrating FoxP3+ Tregs predict favorable outcome in colorectal cancer patients: a meta-analysis. Oncotarget. 2017;8(43):75361–71. https://doi.org/10.18632/oncotarget.17722 .
doi: 10.18632/oncotarget.17722
pubmed: 29088871
pmcid: 5650426
Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006;12(18):5423–34. https://doi.org/10.1158/1078-0432.CCR-06-0369 .
doi: 10.1158/1078-0432.CCR-06-0369
pubmed: 17000676
Kobayashi N, Hiraoka N, Yamagami W, et al. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res. 2007;13(3):902–11. https://doi.org/10.1158/1078-0432.CCR-06-2363 .
doi: 10.1158/1078-0432.CCR-06-2363
pubmed: 17289884
Ladoire S, Martin F, Ghiringhelli F. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother. 2011;60(7):909–18. https://doi.org/10.1007/s00262-011-1046-y .
doi: 10.1007/s00262-011-1046-y
pubmed: 21644034
Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434–52. https://doi.org/10.1016/j.immuni.2018.03.014 .
doi: 10.1016/j.immuni.2018.03.014
pubmed: 29562194
pmcid: 7116507
Li Y, Liang L, Dai W, et al. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Mol Cancer. 2016;15(1):55. https://doi.org/10.1186/s12943-016-0539-x .
doi: 10.1186/s12943-016-0539-x
pubmed: 27552968
pmcid: 4995750
Kim JH, Park HE, Cho N-Y, Lee HS, Kang GH. Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers. Br J Cancer. 2016;115(4):490–6. https://doi.org/10.1038/bjc.2016.211 .
doi: 10.1038/bjc.2016.211
pubmed: 27404452
pmcid: 4985354
Rosenbaum MW, Bledsoe JR, Morales-Oyarvide V, Huynh TG, Mino-Kenudson M. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Mod Pathol. 2016;29(9):1104–12. https://doi.org/10.1038/modpathol.2016.95 .
doi: 10.1038/modpathol.2016.95
pubmed: 27198569
Lee LH, Cavalcanti MS, Segal NH, et al. Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. Mod Pathol. 2016;29(11):1433–42. https://doi.org/10.1038/modpathol.2016.139 .
doi: 10.1038/modpathol.2016.139
pubmed: 27443512
pmcid: 5083129
Masugi Y, Nishihara R, Yang J, et al. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut. 2017;66(8):1463–73. https://doi.org/10.1136/gutjnl-2016-311421 .
doi: 10.1136/gutjnl-2016-311421
pubmed: 27196573
Yomoda T, Sudo T, Kawahara A, et al. The immunoscore is a superior prognostic tool in stages II and III colorectal cancer and is significantly correlated with programmed death-ligand 1 (PD-L1) expression on tumor-infiltrating mononuclear cells. Ann Surg Oncol. 2019;26(2):415–24. https://doi.org/10.1245/s10434-018-07110-z .
doi: 10.1245/s10434-018-07110-z
pubmed: 30569297
Eriksen AC, Sørensen FB, Lindebjerg J, et al. Programmed death Ligand-1 expression in stage II colon cancer—experiences from a nationwide population-based cohort. BMC Cancer. 2019;19(1):142. https://doi.org/10.1186/s12885-019-5345-6 .
doi: 10.1186/s12885-019-5345-6
pubmed: 30755167
pmcid: 6373021
Liu S, Gönen M, Stadler ZK, et al. Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas. Mod Pathol. 2019;32(1):110–21. https://doi.org/10.1038/s41379-018-0114-7 .
doi: 10.1038/s41379-018-0114-7
pubmed: 30166615
Lee SJ, Jun S-Y, Lee IH, et al. CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer. J Cancer Res Clin Oncol. 2018;144(6):1005–14. https://doi.org/10.1007/s00432-018-2620-x .
doi: 10.1007/s00432-018-2620-x
pubmed: 29520442
Miller TJ, Anyaegbu CC, Lee-Pullen TF, Spalding LJ, Platell CF, McCoy MJ. PD-L1+ dendritic cells in the tumor microenvironment correlate with good prognosis and CD8+ T cell infiltration in colon cancer. Cancer Sci. 2021;112(3):1173–83. https://doi.org/10.1111/cas.14781 .
doi: 10.1111/cas.14781
pubmed: 33345422
pmcid: 7935795
Burnell SEA, Capitani L, MacLachlan BJ, Mason GH, Gallimore AM, Godkin A. Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity. Immunother Adv. 2022;2(1):ltab025. https://doi.org/10.1093/immadv/ltab025 .
doi: 10.1093/immadv/ltab025
pubmed: 35265944
Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24–34. https://doi.org/10.1056/NEJMoa2109970 .
doi: 10.1056/NEJMoa2109970
pubmed: 34986285
Rhyner Agocs G, Assarzadegan N, Kirsch R, et al. LAG-3 expression predicts outcome in stage II colon cancer. J Pers Med. 2021. https://doi.org/10.3390/jpm11080749 .
doi: 10.3390/jpm11080749
pubmed: 34442393
pmcid: 8398428
Zhou G, Noordam L, Sprengers D, et al. Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer. Oncoimmunology. 2018;7(7):e1448332. https://doi.org/10.1080/2162402X.2018.1448332 .
doi: 10.1080/2162402X.2018.1448332
pubmed: 29900067
pmcid: 5993483
Chen J, Chen Z. The effect of immune microenvironment on the progression and prognosis of colorectal cancer. Med Oncol. 2014;31(8):82. https://doi.org/10.1007/s12032-014-0082-9 .
doi: 10.1007/s12032-014-0082-9
pubmed: 25034363
Singhal S, Stadanlick J, Annunziata MJ, et al. Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer. Sci Transl Med. 2019. https://doi.org/10.1126/scitranslmed.aat1500 .
doi: 10.1126/scitranslmed.aat1500
pubmed: 30760579
pmcid: 6800123
Lu D, Ni Z, Liu X, et al. Beyond T cells: understanding the role of PD-1/PD-L1 in tumor-associated macrophages. J Immunol Res. 2019;2019:1919082. https://doi.org/10.1155/2019/1919082 .
doi: 10.1155/2019/1919082
pubmed: 31781673
pmcid: 6875348
Shabo I, Stål O, Olsson H, Doré S, Svanvik J. Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival. Int J Cancer. 2008;123(4):780–6. https://doi.org/10.1002/ijc.23527 .
doi: 10.1002/ijc.23527
pubmed: 18506688
Shabo I, Olsson H, Elkarim R, Sun X-F, Svanvik J. Macrophage infiltration in tumor stroma is related to tumor cell expression of CD163 in colorectal cancer. Cancer Microenviron. 2014;7(1–2):61–9. https://doi.org/10.1007/s12307-014-0145-7 .
doi: 10.1007/s12307-014-0145-7
pubmed: 24771466
pmcid: 4150873
Shabo I, Olsson H, Sun X-F, Svanvik J. Expression of the macrophage antigen CD163 in rectal cancer cells is associated with early local recurrence and reduced survival time. Int J Cancer. 2009;125(8):1826–31. https://doi.org/10.1002/ijc.24506 .
doi: 10.1002/ijc.24506
pubmed: 19582880
Anderson P, Aptsiauri N, Ruiz-Cabello F, Garrido F. HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy. Cell Mol Immunol. 2021;18(3):556–65. https://doi.org/10.1038/s41423-021-00634-7 .
doi: 10.1038/s41423-021-00634-7
pubmed: 33473191
pmcid: 8027055
Løvig T, Andersen SN, Thorstensen L, et al. Strong HLA-DR expression in microsatellite stable carcinomas of the large bowel is associated with good prognosis. Br J Cancer. 2002;87(7):756–62. https://doi.org/10.1038/sj.bjc.6600507 .
doi: 10.1038/sj.bjc.6600507
pubmed: 12232760
pmcid: 2364272
Sconocchia G, Eppenberger-Castori S, Zlobec I, et al. HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker. Neoplasia. 2014;16(1):31–42. https://doi.org/10.1593/neo.131568 .
doi: 10.1593/neo.131568
pubmed: 24563618
pmcid: 3924546
Diederichsen ACP, Hjelmborg JVB, Christensen PB, Zeuthen J, Fenger C. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother. 2003;52(7):423–8. https://doi.org/10.1007/s00262-003-0388-5 .
doi: 10.1007/s00262-003-0388-5
pubmed: 12695859
Möller P, Momburg F, Koretz K, et al. Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma. Cancer Res. 1991;51(2):729–36.
pubmed: 1985791